In 2023, the import of insulin not in dosage forms to France stood at X million US dollars. The forecast for 2024 indicates a gradual increase with the value reaching 1.1418 million US dollars. The year-on-year growth for 2025 is projected at 3.64%, continuing with similar growth to 1.2238 million in 2026, representing a rise of 3.42%. By 2027, the forecasted increase is 3.25%, peaking at 1.2636 million. For 2028, a growth rate of 3.08% is expected, reaching 1.3026 million US dollars. Over the five-year period, the compound annual growth rate (CAGR) is approximately 3.35%.
Future trends to watch for include potential shifts in insulin supply chains, technological advancements in insulin production, and regulatory changes affecting import tariffs. Additionally, the development of alternative treatments for diabetes could influence market dynamics and import levels. Monitoring these factors will be crucial for stakeholders in the pharmaceutical and healthcare sectors.
